PL2083863T3 - Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej - Google Patents

Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej

Info

Publication number
PL2083863T3
PL2083863T3 PL07867199T PL07867199T PL2083863T3 PL 2083863 T3 PL2083863 T3 PL 2083863T3 PL 07867199 T PL07867199 T PL 07867199T PL 07867199 T PL07867199 T PL 07867199T PL 2083863 T3 PL2083863 T3 PL 2083863T3
Authority
PL
Poland
Prior art keywords
infants
tgf
antibodies
beta
risk
Prior art date
Application number
PL07867199T
Other languages
English (en)
Inventor
James B Streisand
Jesse D Roberts Jr
Original Assignee
Genzyme Corp
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Massachusetts Gen Hospital filed Critical Genzyme Corp
Publication of PL2083863T3 publication Critical patent/PL2083863T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07867199T 2006-10-03 2007-10-03 Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej PL2083863T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82793306P 2006-10-03 2006-10-03
EP07867199.7A EP2083863B1 (en) 2006-10-03 2007-10-03 Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
PCT/US2007/021234 WO2008060371A1 (en) 2006-10-03 2007-10-03 USE OF TGF-β ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA

Publications (1)

Publication Number Publication Date
PL2083863T3 true PL2083863T3 (pl) 2015-08-31

Family

ID=39217964

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15154393T PL2918288T3 (pl) 2006-10-03 2007-10-03 Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej
PL07867199T PL2083863T3 (pl) 2006-10-03 2007-10-03 Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15154393T PL2918288T3 (pl) 2006-10-03 2007-10-03 Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej

Country Status (10)

Country Link
US (3) US8642034B2 (pl)
EP (3) EP3254696A1 (pl)
CN (2) CN101553254A (pl)
DK (2) DK2083863T3 (pl)
ES (2) ES2538265T3 (pl)
HU (1) HUE035575T2 (pl)
IL (2) IL197797A (pl)
MX (1) MX2009003518A (pl)
PL (2) PL2918288T3 (pl)
WO (1) WO2008060371A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140134181A1 (en) * 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
LT2971048T (lt) 2013-03-11 2019-02-25 Genzyme Corporation Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
WO2017044302A1 (en) * 2015-09-09 2017-03-16 Rush University Medical Center Compositions and methods for treating bone diseases
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
ES2948647T3 (es) 2017-05-04 2023-09-15 Acceleron Pharma Inc Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
CA3075688A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS606629A (ja) 1983-06-23 1985-01-14 Sumitomo Chem Co Ltd ホルムアルデヒドの製造法
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
JP2887325B2 (ja) 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション デコリンによる細胞増殖の抑制
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
FI921353A0 (fi) 1989-09-29 1992-03-27 Jolla Cancer Res Found Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris.
EP0502036B1 (en) 1989-11-22 1995-12-20 Genentech, Inc. Latency associated peptide and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
FR2677038B1 (fr) * 1991-06-03 1994-08-12 Bel Fromageries Additif alimentaire pour l'alimentation humaine et animale et aliments le contenant.
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
WO1993009800A1 (en) 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994009812A1 (en) 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
DE69332026T2 (de) 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
WO1994010187A1 (en) 1992-10-30 1994-05-11 Hsc Research And Development Limited Partnership COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
AU2404695A (en) 1994-05-04 1995-11-29 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997040848A1 (en) 1996-04-30 1997-11-06 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
AU740052B2 (en) 1996-10-25 2001-10-25 Ethicon Inc. Anti-fibrotic agent assay
NZ500284A (en) 1997-04-18 2001-09-28 Biogen Inc Type II TGF-beta receptor fusion proteins
US7779020B2 (en) 2002-03-01 2010-08-17 International Business Machines Corporation Small-footprint applicative query interpreter method, system and program product
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000047102A2 (en) * 1999-02-11 2000-08-17 The General Hospital Corporation COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR100425525B1 (ko) 2000-11-21 2004-03-30 재단법인서울대학교산학협력재단 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트
AU3956002A (en) 2000-11-28 2002-06-11 Childrens Medical Center Determination of risk and treatment of complications of prematurity
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE291020T1 (de) 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
SK287857B6 (sk) 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AU2003209308A1 (en) 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1506191A1 (en) 2002-05-15 2005-02-16 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
EP1575506A4 (en) 2002-07-25 2008-04-23 Scios Inc METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
BR0314196A (pt) 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
EP1543001B1 (en) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
US20060079680A1 (en) 2002-11-22 2006-04-13 Eli Lilly And Company Patent Division Pyrazoloazepine compounds as pharmaceutical agents
WO2004047818A2 (en) 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
WO2004048930A2 (en) 2002-11-22 2004-06-10 Scios, Inc. METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY
WO2004050659A1 (en) 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
AU2003297460A1 (en) 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
US20040266025A1 (en) 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7223766B2 (en) 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
MXPA06008157A (es) 2003-12-24 2007-09-07 Johnson & Johnson Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
AU2005280168A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as TGF-beta inhibitors
AU2005280167A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
EP1812450A2 (en) 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.

Also Published As

Publication number Publication date
WO2008060371A1 (en) 2008-05-22
EP2083863A1 (en) 2009-08-05
ES2647472T3 (es) 2017-12-21
ES2538265T3 (es) 2015-06-18
EP3254696A1 (en) 2017-12-13
EP2918288B1 (en) 2017-08-16
IL251994B (en) 2021-01-31
PL2918288T3 (pl) 2018-02-28
HUE035575T2 (en) 2018-05-28
DK2918288T3 (da) 2017-11-27
EP2083863B1 (en) 2015-03-18
MX2009003518A (es) 2009-08-25
CN104645328A (zh) 2015-05-27
IL197797A0 (en) 2011-08-01
WO2008060371A8 (en) 2008-07-10
EP2918288A1 (en) 2015-09-16
IL251994A0 (en) 2017-06-29
US20170233464A1 (en) 2017-08-17
US20140199399A1 (en) 2014-07-17
US8642034B2 (en) 2014-02-04
CN101553254A (zh) 2009-10-07
US20100008911A1 (en) 2010-01-14
DK2083863T3 (da) 2015-06-22
IL197797A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
PL2083863T3 (pl) Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej
DK2069403T3 (da) Human-antistoffer med høj affinitet for human IL-4 receptor
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
SI2391650T1 (sl) Postopki za zdravljenje protina
ZA201003131B (en) Anti-rsv g protein antibodies
IL228988A (en) Antibody preparations for the treatment of vaccine-related diseases
LT2068889T (lt) Anakinra, naudojama bronchiolito obliteranso sindromo gydymui
PL2152290T3 (pl) Sposoby podawania przeciwciał przeciw IL-5
ZA200808865B (en) Antibody composition and methods for treatment of neoplastic disease
DK2356151T3 (da) Human-antistoffer med høj affinitet for human IL-4 receptor
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
PL1993577T3 (pl) Stosowanie nieulegających trawieniu sacharydów dla zapewnienia niemowlęciu najlepszego startu po narodzinach
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
IL249838A0 (en) Telomerase activating compounds for use in treating diseases related thereto
ZA200905990B (en) Recombinant antibodies for treatment of respriratory syncytial virus infections
PL2061485T3 (pl) Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo
IL195152A (en) Compounds for use in treating diseases of cell culture
EP2200553A4 (en) LIGHT ABSORBENT TRANSPORT DEVICE
IL232011A0 (en) Antibodies to 7egfl and methods of using them
DK2839836T4 (da) Probiotika til anvendelse til reduktion af symptomer på luftvejssygdom
DE112009003128A5 (de) Aggregat zur nutzung alternativer energie
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
EP2152894A4 (en) HUMAN BNP IMMUNE-SPECIFIC ANTIBODIES
EP2094128A4 (en) DISPOSABLE COVER FOR USE IN A PREMATURE COVER